In vitro and in vivo vascular selectivity of lercanidipine and its enantiomers

Journal of Cardiovascular Pharmacology

Volumn 29, Issue SUPPL. 1, 1997, Pages

  Guarneri, L ^a   Sironi, G ^a   Angelico, P ^a   Ibba, M ^a   Greto, L ^a   Colombo, D ^a   Leonardi, A ^a   Testa, R ^a  

^a Recordati SpA   (Italy)

Author keywords

1,4 Dihydropyridines; Calcium antagonists; In vitro and in vivo vascular selectivity; Lercanidipine; Ventricular performance

Indexed keywords

CALCIUM CHANNEL; FELODIPINE; LACIDIPINE; LERCANIDIPINE; NIFEDIPINE; NITRENDIPINE; POTASSIUM CHLORIDE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL REACTIVITY; CALCIUM TRANSPORT; DISEASE CLASSIFICATION; DOG; ENANTIOMER; INOTROPISM; MALE; NONHUMAN; PRIORITY JOURNAL; RABBIT; RAT; STATISTICAL ANALYSIS;

EID: 0031005503     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-199729001-00005     Document Type: Article

References (37)

1. Biel M, Hullin R, Freundner S, et al. Tissue-specific expression of high-voltage-activated dihydropyridine-sensitive L-type calcium channels. Eur J Biochem 1991;200:81-8.
2. Godfraind T, Miller RC, Wibo M. Calcium antagonism and calcium entry-blockade. Pharmacol Rev 1986;38:321-416.
3. Fleckenstein A. Specific pharmacology of calcium in myocardium, cardiac pacemakers and vascular smooth muscle. Annu Rev Pharmacol Toxicol 1977;17:149-66.
4. Opie LH. Calcium channel antagonists. Cardiovasc Drugs Ther 1988;1:411-30.
5. Elkayam U, Weber L, McKay C, Rahimtoola S. Spectrum of acute hemodynamic effects of nifedipine in severe congestive heart failure. Am J Cardiol 1985;56:560-6.
6. Joshi PI, Datal JJ, Ruttley MSJ, Sheridan DJ, Henderson AH. Nifedipine and left ventricular function in beta-blockade patients. Br Heart J 1981;45:457-9.
7. Ludbrook PA, Tiefenbrunn AJ, Sobe BE. Acute hemodynamic response to sublingual nifedipine: dependence on left ventricular function. Circulation 1982;65:489-95.
8. Omtsuka M, Yokota M, Kodama I, Yamada K. New generation dihydropyridine calcium entry blockers in search of greater selectivity for one tissue subtype. Gen Pharmacol 1989;20:539-56.
9. Freedam D, Waters D. Second generation dihydropyridine calcium antagonists. Drugs 1987;34:578-99.
10. Opie LH. Should calcium antagonists be used after myocardial infarction? Ischemia selectivity versus vascular selectivity. Cardiovasc Drugs Ther 1992;6:19-24.
11. Packer M. Second generation calcium channel blockers in the treatment of chronic heart failure: are they any better than their predecessors? Am J Cardiol 1992;14:1339-41.
12. Reicher-Reiss H, Barasch E. Calcium antagonists in patients with heart failure. A Review. Drugs 1991;42:343-64.
13. Ljung B. Vascular selectivity of felodipine. Drugs 1985;29:46-58.
14. Ljung B. Vascular selectivity of felodipine: experimental pharmacology. J Cardiovasc Pharmacol 1990;15:S11-6.
15. Ljung B, Kjellshed A, Oreback B. Vascular versus myocardial selectivity of calcium antagonists studied by concentration-time-effect relations. J Cardiovasc Pharmacol 1987;10(suppl 1):S34-9.
16. Nardi D, Leonardi A, Graziani G, Bianchi G. Asymmetrical diesters of 1,4-dihydropyridine-3,5-dicarboxylic acid. European patent application 0153016B1, 1985.
17. Rimoldi E, Ninci M.A. Therapeutic efficacy of two different dosages of lercanidipine (10 and 20 mg) versus placebo [Abstract]. J Mol Cell Cardiol 1995;27:A387.
18. Richard MO. Pharmacocinétique des antagonistes calciques. Therapie 1993;48:651-7.
19. Guarneri L, Angelico P, Ibba M, et al. Pharmacological in vitro studies of the new 1,4-dihydropyridine calcium antagonist lercanidipine. Arzneimittelforschung 1996;46:15-24.
20. Godfraind T. Cardioselectivity of calcium antagonists. Cardiovasc Drugs Ther 1994;8:353-64.
21. Parmley WW. Efficacy and safety of calcium channel blockers in hypertensive patients with concomitant left ventricular dysfunction. Clin Cardiol 1992;15:235-42.
22. Triggle DJ. Biochemical and pharmacologic differences among calcium channel antagonists: clinical implications. In: Epstein M, ed. Calcium antagonists in clinical medicine. Philadelphia: Hanley and Belfus, 1992:1-27.
23. Triggle DJ. Calcium channel antagonists: mechanism of action, vascular selectivities, and clinical relevance. Cleveland Clin J Med 1992;59:617-27.
24. Boyd RA, Giacomini JC, Giacomini KM. Species differences in the negative inotropic responses of 1,4-dihydropyridine calcium channel blockers in myocardium. J Cardiovasc Pharmacol 1988;12:650-7.
25. Magno M, Gallix P, Cavero I. Intervessels (arterial and veins) and heart/vessel selectivities of therapeutically used calcium entry blockers: variable, vessel-dependent indexes. J Pharmacol Exp Ther 1995;275:1157-66.
26. Sun J, Triggle DJ. Calcium channel antagonists: cardiovascular selectivity of action. J Pharmacol Exp Ther 1995;274:419-26.
27. Arrowsmith JE, Campbell SF, Cross PE, et al. Long-acting dihydropyridine calcium antagonists. 1.2-Alkoxymethyl derivatives incorporating basic substituents. J Med Chem 1986;29: 1696-702.
28. Fricke U, Klaus W, Stein W. Novel halogenated dihydropyridine derivatives with high vascular selectivity. Naunyn Schmiedebergs Arch Pharmacol 1988;338:449-54.
29. Godfraind T, Morel N, Wibo M. Tissue specificity of dihydropyridine calcium antagonists in human isolated tissues. Trends Pharmacol Sci 1988;9:37-9.
30. Godfraind T, Salomone S, Dessy C, Verheish B, Dion R, Schoevaerts JC. Selectivity scale of calcium antagonists in the human cardiovascular system based on in vitro studies. J Cardiovasc Pharmacol 1992;20(suppl 5):S34-S41.
31. Kojda G, Klaus W, Werner G, Fricke V. The influence of the 3-ester side chain variation on the cardiovascular profile of nitrendipine in porcine isolated trabeculae and coronary arteries. Naunyn Schmiedebergs Arch Pharmacol 1991;344:488-94.
32. Perez-Vizcaino F, Tamargo J, Hof RP, Ruegg UT. Vascular selectivity of seven prototype calcium antagonists: a study at the single cell level. J Cardiovasc Pharmacol 1993;22:768-75.
33. Cheng CP, Noda T, Nordlander M, Ohno M, Little WC. Comparison of effects of dihydropyridine calcium antagonists on left ventricular systolic and diastolic performance. J Pharmacol Exp Ther 1994;268:1232-41.
34. Wibo M. Mode of action of calcium antagonists: voltage-dependence and kinetics of drug-receptor interaction. Pharmacol Toxicol 1989;65:1-8.
35. Morel N, Godfraind T. Prolonged depolarization increases the pharmacological effect of dihydropyridines and their binding affinity for calcium channels of vascular smooth muscle. J Pharmacol Exp Ther 1987;243:711-5.
36. Bean BP. Nitrendipine block of cardiac calcium channels: high-affinity binding to the inactivated state. Proc Natl Acad Sci USA 1984;81:6388-92.
37. Bianchi G, Passoni A, Griffini PL. Effects of a new calcium antagonist, Rec 15/2375, on cardiac contractility of conscious rabbits. Pharmacol Res 1989;21:193-200.